Showing 9571-9580 of 20338 results for "".
- Iron Oxides in Tinted Sunscreens May Improve Hyperpigmentation Protection: Studyhttps://reachmd.com/news/iron-oxides-in-tinted-sunscreens-may-improve-hyperpigmentation-protection-study/2487035/A literature review and product analysis published in the Journal of Drugs in Dermatology highlighted growing evidence supporting the use of iron oxides in tinted sunscreens for managing hyperpigmentation, while also identif
- Oral Iptacopan in C3 Glomerulopathyhttps://reachmd.com/news/oral-iptacopan-in-c3-glomerulopathy/2487023/Key Takeaways At 6 months, iptacopan was associated with lower proteinuria than placebo, and the prespecified efficacy endpoint was met. Treatment-emergent adverse events occurred in both groups, were mostly mild or moderate, and no deaths, discontinua
- NeuroSAFE Guided RARP Improves Function in Localized Prostate Cancerhttps://reachmd.com/news/neurosafe-guided-rarp-improves-function-in-localized-prostate-cancer/2487017/Key Takeaways NeuroSAFE-guided RARP was associated with better 12-month patient-reported erectile function than standard surgery. Lower ICIQ scores, indicating better urinary continence, were reported at 3 months, with no significant between-group diff
- Ketamine-Enhanced MORE Trial Reports Fewer Drug Use Instanceshttps://reachmd.com/news/ketamine-enhanced-more-trial-reports-fewer-drug-use-instances/2487016/Key Takeaways MORE plus ketamine was associated with fewer drug use instances after treatment and lower craving at follow-up than MORE alone. No serious ketamine-related adverse events occurred, and between-group differences were not reported for distr
- Late Outcomes After Pediatric Acute Kidney Injuryhttps://reachmd.com/news/late-outcomes-after-pediatric-acute-kidney-injury/2486992/Key Takeaways Pooled incidences after AKI were 17% for CKD, 6% for mortality, 20% for proteinuria, and 16% for hypertension. Across 23 comparator studies with follow-up from 3 months to 18 years, AKI was associated with higher odds of CKD and mortality
- AI-Supported Mammography Met Noninferiority For Interval Cancershttps://reachmd.com/news/ai-supported-mammography-met-noninferiority-for-interval-cancers/2486982/Key Takeaways AI-supported screening had a non-inferior interval cancer rate versus standard double reading. Sensitivity was higher with AI support, while specificity was the same in both groups. Investigators also described fewer interval can
- TORPIDO 30/60 Trial Compares Initial Oxygen in Preterm Resuscitationhttps://reachmd.com/news/torpido-3060-trial-compares-initial-oxygen-in-preterm-resuscitation/2486971/Key Takeaways The primary composite outcome was similar between the two starting FiO2 groups. This was a multicountry randomized comparison across 31 maternity hospitals in 6 countries among infants due at 23 to 28 weeks' gestation. Escalation
- Aging Cohort Analysis IDs Predictors of Stronger Epidermal Barrier Functionhttps://reachmd.com/news/aging-cohort-analysis-ids-predictors-of-stronger-epidermal-barrier-function/2486981/A large population-based analysis from the Baltimore Longitudinal Study of Aging identified several demographic factors associated with stronger skin barrier function, according to findings presented by Katrina Abuabara, MD, MSCE, and colleagues.
- Do Recommended PAN Investigations Differentiate Cases From Controls?https://reachmd.com/news/do-recommended-pans-investigations-differentiate-cases-from-controls/2486972/Key Takeaways Abnormal laboratory findings were common in both groups, and recommended blood and throat testing did not distinguish PANS from idiopathic OCD and or tic disorder controls. In the PANS subgroup, CSF, MRI, and EEG findings were largely non
- Darvadstrocel Findings in ADMIRE CD II Phase 3 Trialhttps://reachmd.com/news/darvadstrocel-admire-cd-ii-phase-3-trial/2486950/Key Takeaways A phase 3 double-blind placebo-controlled randomized trial enrolled adults with complex perianal fistulizing Crohn's disease after inadequate response to immunosuppressive agents or biologics and used standardized local procedures. Week 2